secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2025-02-10T23:59:59+00:00
Accession:  0001140361-25-003645
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Grace Therapeutics: Phase 3 STRIVE-ON trial meets endpoint; announces up to $30M private placement
--------------------------------------------------------------------------------

- Phase 3 STRIVE-ON safety trial met primary endpoint: 19% reduction in clinically significant hypotension vs oral nimodipine; NDA submission expected H1 2025.
- Private placement of up to ~$30M gross proceeds ($15M upfront + up to $15M from warrant exercise); led by Nantahala Capital and ADAR1 Partners.
- Net proceeds ~$13.8M after fees; expected close Feb 11, 2025; funds for general corporate purposes and GTx-104 pre-commercial development.
- 54% of GTx-104 patients achieved ≥95% relative dose intensity vs 8% on oral nimodipine; favorable functional outcomes and fewer ICU days observed.
- Common warrants exercisable at $3.395/share; expire on earlier of 60 days post-FDA approval or Sep 25, 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036125003645/0001140361-25-003645-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036125003645/ef20043150_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-003645

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer